Zogenix initiated with a Buy at Guggenheim. Guggenheim analyst Yatin Suneja initiated Zogenix with a Buy rating and $70 price target, citing his view that lead clinical asset Fintepla has shown “impressive” antiepileptic properties with a favorable risk-benefit profile. Although Dravet Syndrome is likely to be the first approved indication, Suneja believes the drug’s full potential lies in its applicability across a variety of treatment resistant seizure disorders, he tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.